Abstract: A Twin Immune Cell Engager (TWICE) is a kit or composition for treating cancer comprising a first component and second component. Each component comprises a targeting moiety that binds a tumor antigen expressed by the cancer or an antigen expressed by a non-cancer cell in the tumor microenvironment. In some embodiments, the first and second components each comprise an immune cell binding domain capable of immune cell binding activity when binding the immune cell binding domain in the other component, and a complementary binding domain capable of binding to a complementary antigen when binding the complementary binding domain in the other component. In some embodiments, the first and/or second components comprise a complementary functional domain with activity when targeted to the cancer cell or its microenvironment. The present TWICE complexes offer a unique ability to combine multiple functions into a two-component complex that becomes activated in the tumor microenvironment.

Abstract: A Twin Immune Cell Engager (TWICE) is a kit or composition for treating cancer comprising a first component and second component. Each component comprises a targeting moiety that binds a tumor antigen expressed by the cancer or an antigen expressed by a non-cancer cell in the tumor microenvironment. In some embodiments, the first and second components each comprise an immune cell binding domain capable of immune cell binding activity when binding the immune cell binding domain in the other component, and a complementary binding domain capable of binding to a complementary antigen when binding the complementary binding domain in the other component. In some embodiments, the first and/or second components comprise a complementary functional domain with activity when targeted to the cancer cell or its microenvironment.

Abstract: Remote temperature measurement of cookware through a ceramic glass plate using an infrared sensor, taking into account the emissivity of the cookware which is continuously evaluated, and taking into account the temperature of the ceramic glass plate.

Abstract: A Twin Immune Cell Engager (TWICE) is a kit or composition for treating cancer comprising a first component and second component. Each component comprises a targeting moiety that binds a tumor antigen expressed by the cancer or an antigen expressed by a non-cancer cell in the tumor microenvironment. In some embodiments, the first and second components each comprise an immune cell binding domain capable of immune cell binding activity when binding the immune cell binding domain in the other component, and a complementary binding domain capable of binding to a complementary antigen when binding the complementary binding domain in the other component. In some embodiments, the first and/or second components comprise a complementary functional domain with activity when targeted to the cancer cell or its microenvironment. The present TWICE complexes offer a unique ability to combine multiple functions into a two-component complex that becomes activated in the tumor microenvironment.

Abstract: A vacuum chamber (2) for a direct air capture process and enclosing an interior space (13) for housing an adsorber structure (1) is given comprising a contiguous circumferential wall structure (115) along an axis (15), which circumferential wall structure (115) in an axial direction is closed by an inlet and an outlet axial wall (116), respectively. Both axial walls (116) comprise at least one closing stainless steel lid (6) allowing for, in an open position, gas to be circulated through the vacuum chamber (2) for passing an adsorber structure (1), and, in a closed position, to close the interior space (13) and to allow evacuation of the interior space (13) down to pressure of 500 mbarabs or less.

Abstract: A lower nozzle for use in a nuclear fuel assembly provided. The lower nozzle is of the type having an axis and comprising a transverse lower tie plate for channeling the coolant through the lower tie plate and a tubular skirt extending axially from the periphery of the lower tie plate, the skirt delimiting an axial housing closed at one end by the lower tie plate and open at the opposite end, a debris filter configured for axial insertion in the housing and snap-fit springs for retaining the debris filter in the housing after insertion. The springs are configured to shift the debris filter axially towards the lower tie plate.

Abstract: A vacuum chamber (2) for a direct air capture process and enclosing an interior space (13) for housing an adsorber structure (1) is given comprising a contiguous circumferential wall structure (115) along an axis (15), which circumferential wall structure (115) in an axial direction is closed by an inlet and an outlet axial wall (116), respectively, both axial walls (116) comprising at least one closing stainless steel lid (6) allowing for, in an open position, gas to be circulated through the vacuum chamber (2) for passing an adsorber structure (1), and, in a closed position, to close the interior space (13) and to allow evacuation of the interior space (13) down to pressure of 500 mbarabs or less.

Abstract: The strip is of the type comprising a wall portion for delimiting a cell for receiving a fuel rod and allowing flow of a coolant upwardly through the spacer grid, a spring provided on the wall portion for biasing a fuel rod extending through the cell away from the wall portion, the spring being cut out in the strip and delimited by a slot and a motion limiter formed in the strip on the wall portion to limit motion of a fuel rod received in the cell towards the wall portion against action of the spring. According to one aspect of the invention, the motion limiter is located on an edge of the slot opposite the spring and defines a risen portion on the edge.

Abstract: Disclosed are immunogenic Nogo receptor-1 polypeptides, Nogo receptor-1 antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof and nucleic acids encoding the same. Also disclosed are Nogo receptor antagonist polynucleotides. Also disclosed are compositions comprising, and methods for making and using, such Nogo receptor antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof, nucleic acids encoding the same and antagonist polynucleotides.

Abstract: Disclosed are immunogenic Nogo receptor-1 polypeptides, Nogo receptor-1 antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof and nucleic acids encoding the same. Also disclosed are Nogo receptor antagonist polynucleotides. Also disclosed are compositions comprising, and methods for making and using, such Nogo receptor antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof, nucleic acids encoding the same and antagonist polynucleotides.

Abstract: Disclosed are immunogenic Nogo receptor-1 polypeptides, Nogo receptor-1 antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof and nucleic acids encoding the same. Also disclosed are Nogo receptor antagonist polynucleotides. Also disclosed are compositions comprising, and methods for making and using, such Nogo receptor antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof, nucleic acids encoding the same and antagonist polynucleotides.

Abstract: Methods for high level expression of active lymphotoxin-? receptor immunoglobulin chimeric proteins and their purification.

Abstract: The geometric dimensions and shape of a device for removing solid particles from the cooling medium that is circulated in the primary circuit of a nuclear reactor, in particular a boiling water nuclear reactor, are such that the device can be inserted in lieu of a fuel element or fuel assembly into an empty fuel element or assembly position of the reactor core of the nuclear reactor.

Abstract: The strip is of the type comprising a wall portion for delimiting a cell for receiving a fuel rod and allowing flow of a coolant upwardly through the spacer grid, a spring provided on the wall portion for biasing a fuel rod extending through the cell away from the wall portion, the spring being cut out in the strip and delimited by a slot and a motion limiter formed in the strip on the wall portion to limit motion of a fuel rod received in the cell towards the wall portion against action of the spring. According to one aspect of the invention, the motion limiter is located on an edge of the slot opposite the spring and defines a risen portion on the edge.

Abstract: Disclosed are immunogenic Nogo receptor-1 polypeptides, Nogo receptor-1 antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof and nucleic acids encoding the same. Also disclosed are Nogo receptor antagonist polynucleotides. Also disclosed are compositions comprising, and methods for making and using, such Nogo receptor antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof, nucleic acids encoding the same and antagonist polynucleotides.

Abstract: A lower nozzle for use in a nuclear fuel assembly provided. The lower nozzle is of the type having an axis and comprising a transverse lower tie plate for channelling the coolant through the lower tie plate and a tubular skirt extending axially from the periphery of the lower tie plate, the skirt delimiting an axial housing closed at one end by the lower tie plate and open at the opposite end, a debris filter configured for axial insertion in the housing and snap-fit springs for retaining the debris filter in the housing after insertion. The springs are configured to shift the debris filter axially towards the lower tie plate.

Abstract: The compositions and methods of the present invention are based, in part, on our discovery that an effector function mediated by an Fc-containing polypeptide can be altered by modifying one or more amino acid residues within the polypeptide (by, for example, electrostatic optimization). The polypeptides that can be generated according to the methods of the invention are highly variable, and they can include antibodies and fusion proteins that contain an Fc region or a biologically active portion thereof.

Abstract: This invention relates to methods of treating disease with soluble inhibitors of the lymphotoxin pathway having improved properties. This invention also relates to improved LTBR-Ig fusion proteins, and pharmaceutical compositions thereof.

Abstract: Methods for high level expression of active lymphotoxin-? receptor immunoglobulin chimeric proteins and their purification.

Abstract: This invention relates to methods of treating disease with soluble inhibitors of the lymphotoxin pathway having improved properties. This invention also relates to improved LTBR-Ig fusion proteins, and pharmaceutical compositions thereof.